Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials - ScienceDirect
Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon - Cytotherapy
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
FDA Advisory Committee Recommends Approval of CAR-T Cell Therapy and Two New Biosimilars | Biosimilars Law Bulletin
FDA Panel Votes Unanimously in Favor of First CAR-T Cancer Therapy | RAPS
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
FDA Panel Unanimously Recommends Approval for Novartis' CAR-T Therapy CTL019
The Process of CAR-T Cell Therapy | Novartis
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials - ScienceDirect
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy | Nature Communications
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma | Nature Communications
PDF) Global regulatory challenges of CAR T-cell therapies: approval, pricing, and access
Novartis CEO opens door to cancer patient demanding 'fair' CAR-T pricing | Fierce Pharma
Racing toward a historic CAR-T approval, Novartis wins unanimous FDA panel backing | Fierce Pharma
ONCOLOGIC DRUGS ADVISORY COMMITTEE BRIEFING DOCUMENT Tisagenlecleucel (CTL019) for the TREATMENT OF PEDIATRIC AND YOUNG ADULT PA
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
CAR T-Cell Therapy Hits Prime Time; Challenges Remain
The biological basis and clinical symptoms of CAR-T therapy-associated toxicites | Cell Death & Disease
Gene Therapy Reviews Return To US FDA Advisory Committee Schedule :: Pink Sheet
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy | Nature Reviews Clinical Oncology
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials - ScienceDirect
FDA staffers like Sandoz' biosimilarity data for copy of Amgen's Enbrel | Fierce Pharma
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell | Nature Medicine
